Revenue Breakdown
Composition ()
No data
Revenue Streams
IDEXX Laboratories Inc (IDXX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is CAG Diagnostics recurring revenue, accounting for 79.0% of total sales, equivalent to $873.27M. Other significant revenue streams include IDEXX VetLab consumables and Reference laboratory diagnostic and consulting services. Understanding this composition is critical for investors evaluating how IDXX navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, IDEXX Laboratories Inc maintains a gross margin of 60.35%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 28.94%, while the net margin is 22.76%. These profitability ratios, combined with a Return on Equity (ROE) of 66.20%, provide a clear picture of how effectively IDXX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, IDXX competes directly with industry leaders such as BDX and EW. With a market capitalization of $52.29B, it holds a leading position in the sector. When comparing efficiency, IDXX's gross margin of 60.35% stands against BDX's 45.91% and EW's 78.15%. Such benchmarking helps identify whether IDEXX Laboratories Inc is trading at a premium or discount relative to its financial performance.
